ADOCIA SAS (ADOC.PA)

FR0011184241 - Common Stock

7.89  +0.21 (+2.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADOC. ADOC was compared to 81 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC has a correct valuation and a medium growth rate.



0

1. Profitability

1.1 Basic Checks

ADOC had negative earnings in the past year.
ADOC had a negative operating cash flow in the past year.
In the past 5 years ADOC reported 4 times negative net income.
In the past 5 years ADOC reported 4 times negative operating cash flow.

1.2 Ratios

ADOC has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADOC has more shares outstanding
ADOC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADOC has been reduced compared to a year ago.

2.2 Solvency

ADOC has an Altman-Z score of -3.09. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
ADOC has a worse Altman-Z score (-3.09) than 75.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.09
ROIC/WACCN/A
WACC6.74%

2.3 Liquidity

ADOC has a Current Ratio of 1.05. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC has a worse Current ratio (1.05) than 84.29% of its industry peers.
A Quick Ratio of 1.04 indicates that ADOC should not have too much problems paying its short term obligations.
ADOC's Quick ratio of 1.04 is on the low side compared to the rest of the industry. ADOC is outperformed by 81.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 1.04

5

3. Growth

3.1 Past

ADOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.87%, which is quite impressive.
The Revenue has grown by 692.73% in the past year. This is a very strong growth!
ADOC shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.08% yearly.
EPS 1Y75.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.29%
Revenue growth 1Y692.73%
Revenue growth 3Y74.81%
Revenue growth 5Y-10.08%
Revenue growth Q2Q293.28%

3.2 Future

Based on estimates for the next years, ADOC will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.26% on average per year.
Based on estimates for the next years, ADOC will show a very strong growth in Revenue. The Revenue will grow by 22.61% on average per year.
EPS Next Y254.92%
EPS Next 2Y122.78%
EPS Next 3Y67.38%
EPS Next 5Y18.26%
Revenue Next Year115.73%
Revenue Next 2Y84.53%
Revenue Next 3Y54.39%
Revenue Next 5Y22.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

4

4. Valuation

4.1 Price/Earnings Ratio

ADOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 3.07, the valuation of ADOC can be described as very cheap.
ADOC's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADOC is cheaper than 98.57% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 18.93, ADOC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.07

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADOC's earnings are expected to grow with 67.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y122.78%
EPS Next 3Y67.38%

0

5. Dividend

5.1 Amount

ADOC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ADOCIA SAS

EPA:ADOC (9/22/2023, 7:00:00 PM)

7.89

+0.21 (+2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap90.50M
Analysts82.5
Price Target8.87 (12.42%)
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)0%
PT rev (3m)-15.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-34.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-21.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.07
P/S 7.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)2.57
Fwd EY32.58%
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS1
BVpS-1.13
TBVpS-1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.85%
Cap/Sales 1.34%
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 1.04
Altman-Z -3.09
F-Score4
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)26.38%
Cap/Depr(5y)65.75%
Cap/Sales(3y)16.9%
Cap/Sales(5y)29.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y75.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.29%
EPS Next Y254.92%
EPS Next 2Y122.78%
EPS Next 3Y67.38%
EPS Next 5Y18.26%
Revenue growth 1Y692.73%
Revenue growth 3Y74.81%
Revenue growth 5Y-10.08%
Revenue growth Q2Q293.28%
Revenue Next Year115.73%
Revenue Next 2Y84.53%
Revenue Next 3Y54.39%
Revenue Next 5Y22.61%
EBIT growth 1Y91.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year728.45%
EBIT Next 3Y129.06%
EBIT Next 5YN/A
FCF growth 1Y22.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.04%
OCF growth 3YN/A
OCF growth 5YN/A